TRPML1 Agonist Program
Alzheimer's Disease, Parkinson's Disease, Lysosomal Storage Disorders
Key Facts
About Lysoway Therapeutics
Lysoway Therapeutics is an early-stage, private biotech founded in 2021 and based in Cambridge, USA, targeting a novel mechanism in neurodegeneration. The company is developing highly selective agonists for lysosomal ion channels (TRPML1, TMEM175) to correct the dysfunctional autophagy and lysosomal impairment central to diseases like Alzheimer's and Parkinson's. Leveraging proprietary screening and structure-guided design platforms, Lysoway aims to create first-in-class therapeutics that address core cellular pathology. The company is backed by venture capital firms including 3E Bioventures, Oceanpine Capital, and Highlight Capital, and is led by a team with deep expertise in drug discovery and translational sciences.
View full company profileTherapeutic Areas
Other Alzheimer's Disease, Parkinson's Disease, Lysosomal Storage Disorders Drugs
| Drug | Company | Phase |
|---|---|---|
| TMEM175 Agonist Program | Lysoway Therapeutics | Pre-clinical |